Zevra Cash vs Total Stockholder Equity Analysis
| ZVRA Stock | 9.51 0.00 0.00% |
Zevra Therapeutics financial indicator trend analysis is more than just analyzing Zevra Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zevra Therapeutics is a good investment. Please check the relationship between Zevra Therapeutics Cash and its Total Stockholder Equity accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.
Cash vs Total Stockholder Equity
Cash vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zevra Therapeutics Cash account and Total Stockholder Equity. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Zevra Therapeutics' Cash and Total Stockholder Equity is 0.82. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Zevra Therapeutics, assuming nothing else is changed. The correlation between historical values of Zevra Therapeutics' Cash and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Zevra Therapeutics are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Cash i.e., Zevra Therapeutics' Cash and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.82 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Cash
Cash refers to the most liquid asset of Zevra Therapeutics, which is listed under current asset account on Zevra Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Zevra Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Zevra Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Zevra Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zevra Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.At present, Zevra Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.39, whereas Tax Provision is forecasted to decline to (35.7 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 28.7M | 10.5M | 27.5M | 20.4M | Interest Income | 248K | 760K | 4.6M | 4.8M |
Zevra Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Zevra Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Zevra Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 10.5M | 11.2M | 132.9M | 115.5M | 172.3M | 180.9M | |
| Other Current Liab | 236K | 5.5M | 3.3M | 3.3M | 21.5M | 22.6M | |
| Total Current Liabilities | 5.4M | 7.5M | 4.2M | 11.7M | 73.7M | 77.4M | |
| Total Stockholder Equity | (74.5M) | (66.4M) | 127.1M | 85.8M | 61.9M | 65.0M | |
| Property Plant And Equipment Net | 3.0M | 2.4M | 2.0M | 1.8M | 1.5M | 1.6M | |
| Net Debt | 76.3M | 66.1M | (110.8M) | (51.3M) | 716K | 680.2K | |
| Retained Earnings | (245.7M) | (258.5M) | (267.0M) | (308.6M) | (399.8M) | (379.8M) | |
| Accounts Payable | 1.1M | 1.2M | 516K | 3.6M | 14.0M | 14.7M | |
| Cash | 3.2M | 4.2M | 112.3M | 65.5M | 43.0M | 29.5M | |
| Non Current Assets Total | 3.9M | 2.8M | 17.9M | 22.5M | 85.4M | 89.7M | |
| Non Currrent Assets Other | 562K | 527K | 438K | 724K | 9.9M | 10.4M | |
| Cash And Short Term Investments | 3.2M | 4.2M | 112.3M | 82.8M | 43.0M | 40.6M | |
| Common Stock Shares Outstanding | 1.9M | 4.0M | 29.8M | 34.5M | 35.5M | 37.2M | |
| Non Current Liabilities Total | 79.5M | 70.1M | 1.6M | 18.0M | 36.7M | 54.6M | |
| Other Current Assets | 1.6M | 1.5M | 1.2M | 2.8M | 3.1M | 3.2M | |
| Total Liab | 85.0M | 77.6M | 5.8M | 29.7M | 110.5M | 68.7M | |
| Total Current Assets | 6.6M | 8.4M | 115.1M | 93.0M | 86.9M | 48.0M | |
| Short Long Term Debt Total | 79.5M | 70.4M | 1.6M | 14.1M | 43.8M | 52.1M | |
| Net Receivables | 1.9M | 2.6M | 1.5M | 7.2M | 17.4M | 18.2M | |
| Liabilities And Stockholders Equity | 10.5M | 11.2M | 132.9M | 115.5M | 172.3M | 180.9M | |
| Other Stockholder Equity | 171.3M | 192.1M | 394.1M | 428.7M | 461.7M | 484.8M | |
| Short Term Debt | 284K | 889K | 371K | 1.4M | 38.2M | 40.2M | |
| Short Term Investments | 31.4M | 3.3M | 0.0 | 17.4M | 24.7M | 14.7M | |
| Inventory | 1.0 | 224K | 109K | 24.1M | 27.7M | 29.1M | |
| Current Deferred Revenue | 3.8M | 5.5M | 2.5M | 4.7M | 8.3M | 5.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zevra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zevra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zevra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zevra Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.13) | Revenue Per Share 0.575 | Quarterly Revenue Growth 0.276 | Return On Assets (0.33) | Return On Equity (1.31) |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.